Research in focus: Antimicrobial resistance in cystic fibrosis
In October 2020 the Cystic Fibrosis Trust published a research in focus report on antimicrobial resistance (AMR) in cystic fibrosis. While AMR is a concern for us all, people living with CF are particularly vulnerable to it. The report highlights how CF researchers are leading the way in tackling AMR in CF, and how the ground-breaking approaches described in this report will be beneficial for people with CF in the future. Innovations made in tackling AMR in CF will also be applicable to solving AMR for all those with drug-resistant infections.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.